摘要
Entresto是近二十年来全球慢性心力衰竭治疗领域的突破性创新药物,其可同时抑制脑啡肽酶(NEP)和阻断血管紧张素Ⅱ1型受体(AT1受体),降低心力衰竭患者住院与死亡风险。目前心力衰竭的发病机制仍不清楚,心力衰竭患者的死亡率仍居高不下,而Entresto上市可以给临床医生提供新的治疗措施。
Entresto is a breakthrough drug for the treatment of chronic heart failure in the world over the past twenty years. It can simultaneously inhibit neutral endopeptidase（NEP） and block angiotensin Ⅱ type 1 receptor（AT1 receptor）, meanwhile, reduce the risk of hospitalization and death in patients with heart failure. At present, the pathogenesis of heart failure remains unclear and the mortality rate is still high, while Entresto can be listed to provide a new treatment measure for clinicians.
作者
余彬
丁家望
汪心安
YU Bin;DING Jia-wang;WANG Xin-an(Department of Cardiology, the Central People ＇s Hospital in Yichang/the First Medical College of China Three Gorges University, Yichang 443003, Hubei, CHIN)
出处
《海南医学》
CAS
2018年第10期1420-1422,共3页
Hainan Medical Journal
基金
国家自然科学基金(编号:81770456
81400794)
关键词
Entresto
ARNI
心力衰竭
安全性
有效性
Entresto
Angiotensin receptor-neprilysin inhibitors （ARNi）
Heart failure
Safety
Effectiveness
